Therapeutic benefit of lymphadenectomy for advanced ovarian clear cell carcinoma with no preoperative and/or intraoperative lymph node enlargement

Abstract

Synopsis: ［OBJECTIVES］We aimed to investigate the therapeutic benefit of lymphadenectomy［LA］for advanced ovarian clear cell carcinoma［OCCC］with no preoperative and/or intraoperative lymph node enlargement.Key words: Ovarian Neoplasms/surgery, retrospective study, Lymph Node Excision

［METHODS］From 2002 to 2021, we selected patients with newly diagnosed advanced OCCC with no preoperative and/or intraoperative lymph node enlargement. Patients who did not undergo primary surgery, had severe comorbidities, had residual disease after primary surgery, or did not receive postoperative adjuvant chemotherapy were excluded. Overall survival［OS］and recurrence-free survival［RFS］were compared between LA group and no-LA group.

［RESULTS］Sixteen patients met the eligibility criteria for this study. Pelvic and para-aortic LA in 9 cases, and LA was not performed in 7 cases. There were no significant differences in characteristics of the patients between the two groups. The 3-year RFS rate was 55.6% (95%CI 20.4-80.5) in LA group and 57.1% (95%CI 17.2-83.7) in no-LA group (p＝0.78). The 3-year OS rate was 77.8% (95%CI 36.5-93.9) in LA group and 66.7% (95%CI 19.5-90.4) in no-LA group (p＝0.29).

［CONCLUSIONS］LA for patients with advanced OCCC with no preoperative and/or intraoperative lymph node enlargement may not be associated with OS/RFS.